QCG
NAGE icon

Quadrant Capital Group’s Niagen Bioscience NAGE Stock Holding History

Quadrant Capital Group’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79
Closed -$503 – 2826
2025
Q4 		$503 Sell
79
-392
-83% -$2.73K ﹤0.01% 2648
2025
Q3 		$4.39K Buy
+471
New +$4.76K ﹤0.01% 2339

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrant Capital Group's NAGE Position: Q1 2026 in Review

Quadrant Capital Group sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 79 shares — an estimated $503 sold.

Quadrant Capital Group first reported a position in NAGE in Q3 2025 and held it in 2 quarters. The position peaked at $4.39K in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Quadrant Capital Group reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 79 Niagen Bioscience shares in Q1 2026, an estimated $503.
  • Quadrant Capital Group first reported a position in Niagen Bioscience in Q3 2025 and held it in 2 quarters.
  • Quadrant Capital Group's Niagen Bioscience position peaked at $4.39K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.